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Burkholderia pseudomallei (Bp) is an environmental bacterial pathogen that causes 
potentially lethal sepsis in susceptible individuals and is considered a Category B, 
Tier-1 biothreat agent. As such, it is crucial to gain an improved understanding of pro-
tective immunity and potential vaccine candidates. The nature of immune correlates 
dictating why most exposed individuals in endemic regions undergo asymptomatic 
seroconversion while others succumb to life-threatening sepsis is largely uncharted. 
Bp seroreactive, immunogenic proteins have previously been identified by antigen 
microarray. We here set out to conduct an analysis of T-cell recognition of the Bp 
immunome using serodominant antigens represented in the original antigen micro-
array, examining immune correlates of disease in healthy seropositive individuals and 
those with acute disease or in convalescence. By screening a library of 739 overlap-
ping peptides representing the sequences of 20 different Bp antigens, we aimed to 
define immune correlates of protection at the level of immunoprevalent T-cell epitopes. 
Responses to a large number of epitopes were common in healthy seropositive indi-
viduals: we found remarkably broad responsiveness to Bp epitopes, with 235 of 739 
peptides recognized by ≥80% of all tested donors. The cumulative response to Bp 
epitopes in healthy, seropositive, donors from this endemic region were of the order of 
thousands of spot forming cells per million cells, making Bp recognition a significant 
component of the T-cell repertoire. Noteworthy among our findings, analysis revealed 
10 highly immunoprevalent T-cell epitopes, able to induce Bp-specific IFNγ responses 
that were high in responding T-cell frequency within the repertoire, and also common 
across individuals with different human leukocyte antigen types. Acute melioidosis 
patients showed poor T-cell responses to the immunoprevalent epitopes, but acquired 
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responsiveness following recovery from infection. Our findings suggest that a large 
repertoire of CD4 T cells, high in frequency and with broad coverage of antigens and 
epitopes, is important in controlling Bp infection. This offers an attractive potential 
strategy for subunit or epitope-based vaccines.
Keywords: Burkholderia pseudomallei, epitope, T cell, melioidosis, iFnγ
inTrODUcTiOn
Bukholderia pseudomallei (Bp) is a Gram-negative bacterium 
responsible for melioidosis, which causes sepsis in Southeast 
Asia, Northern Australia, and other temperate regions (1). Bp 
is deemed a category B pathogen on the NIAID category A–C 
pathogen list since there are concerns about the potential for 
weaponization in a bioterrorism or biowarfare context (2, 3). 
Although many Bp genomes have now been sequenced, several 
aspects of pathogenicity and immunology of melioidosis are 
poorly characterized (3): this is an intracellular pathogen, pre-
dominantly infecting antigen presenting cells (APCs), such that 
some people suffer no clinical symptoms, while others develop 
sepsis with high mortality. Bp also has the ability to cause recur-
rent disease several decades after initial exposure. As such, it poses 
unresolved questions of adaptive immune control. A disease 
which is challenging to diagnose and which can be rapidly fatal; 
there is a clear need for improved diagnostics, vaccine strategies 
and therapies (2, 4).
Reporting of severe and lethal melioidosis cases has been 
dominated by Thailand, where there have been of the order of 
2,000 lethal cases annually. In light of concerns that other coun-
tries with evidence of environmental Bp may have substantial 
underreporting (e.g., through lack of appropriate clinical micro-
biology), Limmathurotsakul et al. recently presented a compre-
hensive, evidence-based, predictive map of Bp, estimating global 
incidence, and mortality due to melioidosis (5). This integrated 
human and animal melioidosis data with environmental Bp data 
and environmental covariates proposed to affect the presence of 
Bp. The model estimates around 165,000 human cases annually, 
around 90,000 fatal. This suggests that melioidosis cases are 
underreported from around 45 countries in which it is endemic.
While there have been substantial efforts to identify protective 
vaccines for melioidosis, there remains a lack of consensus on the 
most effective vaccine targets and approach (6). The most effec-
tive vaccine candidates appear to be live, attenuated variants of 
Bp, capable of inducing long term protection (7, 8); however, this 
approach may be precluded by safety concerns (9). An alterna-
tive, safer option may be a subunit vaccine encompassing specific 
antigens or epitopes (10). Peptide epitope subunit vaccine offer 
advantages in being relatively easy and inexpensive to produce, 
with the potential to focus immunity on high-frequency effec-
tor populations (11). Any discussion of Bp vaccine candidates, 
whether for global health and/or biodefense applications, must 
necessarily be informed by an understanding of sequence homol-
ogy and cross-reactivity with two other, related, Burkholderia 
species. Burkholderia mallei (Bm), the causative agent in glanders, 
is highly pathogenic and considered a biothreat. Burkholderia 
thailandensis (Bt), on the other hand, is non-pathogenic, may 
confer protective, cross-reactive immunity, and is found in the 
soil in parts of SE Asia and elsewhere (12).
In endemic regions, where many people will be exposed to 
Bp but relatively few develop clinical disease, one has a potential 
opportunity to investigate the nature of protective immunity 
(13). IFNγ-mediated immunity is likely to be important for the 
host response: in mice, IFNγ derived from CD4 and CD8 cells, 
as well as from NK  cells, is critical for survival (14–16). We 
have previously described CD4+ and CD8+ memory T  cells as 
the source of IFNγ in human immunity to Bp antigens (17). We 
recently reported epitopes of flagellin (BPSL3319, FliC) and of the 
alkyl hydroperoxide reductase (BPSL2096, AhpC) of Bp, which 
induced IFNγ production by human CD4 T cells (18, 19).
Several Bp antigens have been tested for humoral and cellular-
mediated immune responses following infection (17, 18, 19, 
20, 21). We previously used a Bp protein microarray to identify 
seroreactive antigens from seropositive individuals and patients 
who had recovered from melioidosis (13). We suggested that 
immune responses against the reported proteins may contribute 
to protection among individuals living in endemic areas, and 
protect those patients who survive severe Bp infection. In the pre-
sent study, we aimed to extend the granularity of this previously 
reported study through comprehensive T-cell epitope mapping, 
using selected proteins from the same array, in Thai seropositive 
and clinical disease cohorts, with a view to delineating patterns of 
T-cell responses at the peptide-MHC (pMHC) level.
MaTerials anD MeThODs
human samples
Blood-bank buffy coats were obtained from the Blood Transfusion 
Center, Khon Kaen Hospital, Khon Kaen, Thailand with ethical 
approval by Khon Kaen University Ethics Committee for Human 
Research (Project no. HE470506). Healthy Bp-seropositive buffy 
coat samples were used on the basis of displaying IHA titers of 
1:40 or greater whereas seronegative samples were <1:40 (22, 23).
Melioidosis patients (defined as Bp culture-positive and dis-
playing clinical signs and symptoms of infection) were recruited 
at Srinagarind Hospital, Khon Kaen University, Khon Kaen, 
Thailand. Patients receiving immunosuppressive therapy, with 
known kidney disease, or HIV-infected, were excluded from the 
study. “Recovered melioidosis” was defined as those individuals 
who had recovered from melioidosis previously diagnosed by iso-
lation of Bp from blood or tissues, completed antibiotic treatment, 
and clinically well. All patients gave informed, written consent 
before blood donation. Peripheral mononuclear cells (PBMCs) 
from donors were isolated by Ficoll-Hypaque (Sigma-Aldrich) 
density gradient centrifugation, and stored at −80oC until used.
TaBle 1 | Listing and details of twenty Burkholderia pseudomallei candidate antigens for T-cell epitope mapping studies
locus tag Protein name number 
of amino 
acids
number of 
overlapping 
peptides
Molecular 
weight (kDa)
subcellular 
localization
number 
of tested 
samples
number of 
analyzed 
samples
BPSL0280 Flagellar hook-associated protein (FlgK) 667 67 67.2 Extracellular (flagella) 55 30
BPSL0919 4-hydroxy-3-methylbut-2-enyl diphosphate reductase 326 33 35.2 Cytoplasmic 50 34
BPSL0999 OmpA family transmembrane protein 215 22 21.4 Outer Membrane 53 47
BPSL1445 Putative lipoprotein 195 18 19.6 Extracellular 45 35
BPSL2096 Hydroperoxide reductase 182 17 20.3 Periplasmic 50 34
BPSL2504 Hydrolase 280 27 30.1 Cytoplasmic 55 37
BPSL2520 Putative exported protein BPSL2520 198 19 21.3 Unknown 45 30
BPSL2522 Outer membrane protein A 224 23 24.1 Outer Membrane 50 35
BPSL2697 Chaperonin (GroEL) 546 54 57 Extracellular 44 23
BPSL2765 Putative OmpA family lipoprotein 170 16 18.6 Surface 46 16
BPSL3319 Flagellin (FliC) 388 38 39.3 Flagellar 51 45
BPSS0477 60-kDa chaperonin (GroEL2) 546 54 56.8 Cytoplasmic 45 35
BPSS0530 Hypothetical protein BPSS0530 453 44 49.9 Cytoplasmic 52 43
BPSS1385 ATP/GTP binding protein 328 32 35.8 Cytoplasmic 51 45
BPSS1492 Burkholderia intracellular motility A (BimA) 516 50 51.7 Outer Membrane 41 25
BPSS1525 Guanine nucleotide exchange factor BopE 261 25 28.7 Extracellular 52 39
BPSS1531 Effector protein (BipC) 419 41 44.3 Periplasmic 50 35
BPSS1532 Cell invasion protein (BipB) 620 61 64.6 Cytoplasmic 45 34
BPSS1599 Type IV pilus biosynthesis protein (PilO) 432 44 47.9 Unknown 52 47
BPSS2141 Periplasmic oligopeptide-binding protein precursor (OppA) 554 54 61.8 Periplasmic 45 30
Total number of peptides 739
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Peptide libraries
Synthetic peptide libraries were used, covering the full length of 
20 candidate Bp proteins as shown in Table  1. Sets of 20-mer 
peptides, overlapping by 10 amino acids, were synthesized by 
GL Biochem (Shanghai, China), based on the sequence of Bp 
K96243 strain. We note that 20 mers are larger than most MHCII 
presented epitopes and that, thus, the peptides may have been 
reprocessed and, indeed, that some peptides may have carried 
more than one epitope. Fine-mapping of minimal epitopes within 
each peptide was beyond the scope of this study. Peptides were 
stored and shipped as stock solutions of 25  mg/mL in DMSO 
(i.e., 1,000×). We have previously confirmed baseline values for 
the addition to PBMC of diluted DMSO in medium or of negative 
control peptides.
Preparation of Paraformaldehyde (PFa) 
Fixed Bp
Live clinical isolate Bp from Thai strain K96243 (24) was grown 
to mid-log phase at 37°C in Luria–Bertani (LB) broth for 18 h. 
Bacteria were washed twice with PBS, then separated into two 
sets for enumeration of number of bacteria by plating on LB agar 
and for PFA fixation with 2% PFA for 1 h at room temperature 
before being stored at −80oC until use. All manipulation of live 
Bp was carried out at laboratory biosafety level 3 (BSL3) under 
US Centers for Disease Control (CDC) regulations for research.
human T-cell epitope Mapping
Burkholderia pseudomallei T-cell epitope mapping by assay of 
responses to individual peptides in IFNγ ELISpot (C.T.L., USA) 
was as previously described (19). In brief, precoated, 96-well 
polyvinylidene difluoride (PVDF) plates (MSIP, Millipore) 
were cultured overnight with 15-µg/mL IFNγ antibody, then 
2.5 million/mL of isolated PBMC, pulsed with killed, intact Bp 
as a positive control, with each peptide at 25  µg/mL, or with 
culture medium as negative control, were added in triplicate, and 
cocultured for 48 h. While we note that CD8 T cells can respond 
to optimal peptide concentrations well below 25  µg/mL, we 
have previously identified this as the optimal concentration for 
large-scale, high-throughput, CD4 screening of peptide libraries, 
without risk of losing responses to low avidity epitopes. IFNγ 
secretion was detected by addition of antihuman-IFNγ detection 
antibody solution at room temperature for 3  h. After washing, 
streptavidin-alkaline phosphatase solution was added to the 
plate for 30 min, and spots were revealed with developer solution 
for 10  min. IFNγ spots were quantified using an Immunospot 
analyzer (C.T.L.). Results were calculated as spot forming cells 
(SFC)/million PBMC.
human leukocyte antigen (hla) Typing
Donor HLA-DRB1 genotypes were analyzed using PCR 
sequence-specific primer (PCR-SSP), using 20 primer pairs (25). 
Primer mixtures comprised a pair of allele-specific primers and a 
pair of 256-bp internal control primers.
hla Binding assay
Human leukocyte antigen-peptide binding across a panel of HLA 
class-II alleles was as previously described (18). Purified HLA-DR 
heterodimers derived from the relevant EBV B-lymphoblastoid 
cell lines were assayed for peptide binding by competitive ELISA 
(26). HLA-DR molecules were diluted with a known, selected, 
binder, biotinylated peptide, and serial dilutions of competitor 
peptides. Unlabeled forms of the biotinylated peptides were 
included as reference peptides, allowing us to assess the validity of 
each experiment. After 24–72 h incubation at 37°C, samples were 
FigUre 1 | Immunoprevalent peptides identified using Burkholderia 
pseudomallei antigen peptide libraries in seropositive healthy donors. 
Peptides were ranked on the basis of % responders from highest to lowest, 
plotted on the left y-axis (blue dashed line represents % responders = total 
number of individuals that responded to a particular peptide/number of 
donors tested). Median spot forming cell (SFC)/106 peripheral mononuclear 
cell (PBMC) is plotted on the right y-axis (black dot represented for median 
SFC/106 PBMCs = sum of total SFC/number of donors tested). Red dashed 
lines indicate the 49 peptides which were recognized by ≥95% of all tested 
donors (dark gray zone), the 235 peptides which were recognized by ≥80% 
of all tested donors (light gray zone).
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neutralized. They were then applied to 96-well Maxisorp ELISA 
plates (Nunc, Denmark) which had been previously coated with 
the HLA-DRα mAb, L243, used at 10  µg/mL. Samples were 
bound to antibody-coated plates for 2  h at room temperature. 
The extent of binding by biotinylated peptide was then detected 
by incubation with streptavidin-alkaline phosphatase conjugate 
(GE-healthcare, Saclay, France), and after washing, by addition 
of 4-methylumbelliferyl phosphate substrate (Sigma, France). 
Fluorescence was assayed at 450 nm, with excitation at 365 nm. 
The peptide concentration that prevented binding of 50% of the 
labeled peptide (IC50) was evaluated. Data are expressed as rela-
tive affinity, as a ratio of the IC50 of test peptide to the IC50 of a 
reference peptide chosen as a high binder to the corresponding 
HLA-DR heterodimer. Mean + SEM were calculated from three 
independent experiments and relative affinities of <20 were con-
sidered high binders and relative affinities of 20–100, moderate 
binders.
statistical analysis
Statistical analysis was performed using Graphpad Prism version 
6 software (GraphPad). The Mann–Whitney U test was applied 
for comparing among independent sample groups. The Wilcoxon 
signed rank test was applied for comparing dependent sample 
groups, P-value  <0.05 was considered statistically significant 
(*P < 0.05, **P < 0.01, and ***P < 0.001).
resUlTs
immunoprevalent T-cell epitopes 
recognized by seropositive healthy 
Donors
We initially addressed human T-cell epitope identification using 
overlapping peptide libraries (27, 28). Protein sequences of 20 
key, serodominant, Bp proteins (13), previously reported by our 
group, were retrieved from the NCBI protein database. Peptide 
libraries were synthesized for each candidate as 20 mers with an 
overlap of 10. The details of peptide libraries are shown in Table 1 
and the strategy for identification of T-cell epitopes is shown in 
supplementary data (Figure S1 in Supplementary Material). We 
screened for induction of T-cell IFNγ responses against each pep-
tide, totaling 739 peptides from 20 Bp antigens; for this we used 
PBMC from healthy, seropositive donors from an endemic area. 
Demographic data and HLA frequency distribution are shown in 
Table S1 in Supplementary Material. Based on our demographic 
data, the HLA distribution of our selected cohort (N = 129) is 
concordant with previous reports from the Khon Kaen region 
of Thailand (25). In each case, PFA fixed, whole Bp (“Fixed Bp”) 
was used as a positive control. Any non/low-responder samples 
showing an IFNγ response to Fixed Bp lower than medium-
only +2 SD cutoff were excluded (Figure S2 in Supplementary 
Material). The results from one representative seropositive donor 
are shown in supplementary data (Figure S3 in Supplementary 
Material). The percent of responders was defined as the number 
of individuals that responded to a peptide divided by the total 
number of individuals tested, multiplied by 100. This gives an 
indication of how common or rare a response to a peptide is in the 
population of Bp seropositive individuals tested. The frequency 
of the T-cell response to a given peptide was taken as the median 
number of IFNγ-producing cells calculated from all donors tested 
(SFC/106 PBMC). This gives an indication of the magnitude of 
the T-cell IFNγ response. Peptide responses were then ranked 
on the basis of the percentage of responders and magnitude of 
response to assess relative immunoprevalence. From this analysis, 
there were 49 peptides that carried T-cell epitopes recognized 
by  ≥95% of all tested seropositive donors, and 235 peptides 
recognized by ≥80% of all tested donors (Figure 1). The list of 
the top 235 commonly recognized peptides is shown in Table S2 
in Supplementary Material. Positive peptide responses tended 
to be of relatively high frequency at around 200–400  SFC/106 
cells, and each seropositive donor tended to respond to multiple 
epitopes, both within and across different Bp antigens. Thus, the 
cumulative response to Bp in healthy seropositive donors from 
an endemic region is, generally, of the order of some thousands 
of SFC/106 cells, making Bp antigen recognition a significant 
component of the T-cell repertoire.
hla class-ii Polymorphism and Patterns 
of response to strongly immunoprevalent 
Bp epitopes
The observation that a large number of Bp epitopes could be 
recognized at high frequency by CD4 T  cells from this Thai, 
seropositive, donor cohort led us to interrogate in more detail 
the possibility that the most commonly recognized epitopes 
must have the ability to bind multiple HLA class-II products for 
presentation (29). We selected 10 of the most commonly recog-
nized immunoprevalent peptides (recognized by  ≥80% of all 
tested donors) from the top 235 peptides (Table 2). The selected 
TaBle 2 | Selected 10 T-cell immunoprevalent peptides of Burkholderia pseudomallei (Bp) identified from seropositive healthy donors using 20 Bp libraries.
locus tag Peptide number location of peptide on protein Peptide sequence region feature % responders
BPSL0999 P14 131–150 NQNPQITASVVGYTDSTGSA OmpA family transmembrane protein 96
BPSL0999 P18 171–190 RGVAANRLSAQGMGASNPIA OmpA family transmembrane protein 94
BPSL2096 P06 51–70 KDFTFVCPTEIVEFAKLAKQ Hydroperoxide reductase 82
BPSL2522 P12 111–130 PAGKQKLDELAAKIQGMNVE Outer membrane protein A 97
BPSL2522 P13 121–140 AAKIQGMNVEVVVATGYTDR Outer membrane protein A 100
BPSL2522 P14 131–150 VVVATGYTDRIGSDKYNDRL Outer membrane protein A 100
BPSS1385 P11 101–120 SNRVMWNDRYDTLLIARDPR ATP/GTP binding protein 98
BPSS1385 P12 131–150 TDFGGLENYKELTGGADPFA ATP/GTP binding protein 93
BPSS1385 P18 171–190 DVPIDPTSIEYLENTSFAEH ATP/GTP binding protein 100
BPSS1531 P12 111–130 HDALVQRHVSLDGAKAAHGE Effector protein BipC 89
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peptides were analyzed for binding to HLA class-II heterodimers, 
including the common SE Asian polymorphisms, HLA DRB1*04, 
07, 09, 11:01, 12:02, 15:01, and 15:02 (25). HLA binding affinities 
were then related to our findings from IFNγ ELISpots (Table 3). 
We found that the selected 10 immunoprevalent peptides showed 
broad HLA class-II binding. HLA-DRB1*15:01 was able to bind 
selected immunoprevalent peptides with high affinities, while 
the closely related variant from the Thai population, HLA-
DRB1*15:02, bound most of the peptides relatively poorly. We 
note that these two alleles of HLA-DR15 are found in roughly 
equal proportions in Thai population (www.allelefrequencies.
net). The heterodimers HLA DRB1*04, 07, 09, 11:01 and 12:02 
tended to bind the immunoprevalent peptides with moderate 
affinity. Some of the immunoprevalent peptides such as p6 from 
hydroperoxide reductase (BPSL2096) and p18 from ATP/GTP 
binding protein (BPSL1385) had the property of binding to 
virtually all the tested HLA class-II heterodimers at moderate to 
high affinity.
comparative responses to 
immunoprevalent Peptides in healthy 
seropositive Donors and in Patients 
during acute Melioidosis and following 
recovery
We then compared T-cell responses to the set of the 10 most 
strongly immunoprevalent peptides in additional cohorts of Thai 
seronegative (S−), seropositive (S+), and recovered (R) melioido-
sis patients. The key question was whether there were features of 
T-cell epitope recognition differentiating between asymptomatic 
seropositives and patients who had recovered from acute, clinical 
disease (Figure 2). T-cell responses to Fixed Bp were similarly 
raised in the seropositive and recovered melioidosis sample sets 
relative to the seronegative group. These results are consistent 
with a previous report from our group (17) (Figure  2A). For 
most of the epitope responses tested, T-cell recognition was 
similar between the seropositive group and the recovered meli-
oidosis group (Figure 2B). However, the response to the OmpA 
BPSL2522 p14 epitope was lower in recovered patients than in 
seropositive healthy donors. This raises the possibility that OmpA 
may be poorly expressed by Bp or poorly processed/presented to 
the immune system during acute melioidosis.
We then investigated T-cell epitope recognition in acute 
septicemic melioidosis patients compared with convalescent 
patients. The magnitude of T-cell response to Fixed Bp was not 
different between groups, arguing against a global shutdown of 
the specific response to bacterial infection during acute sepsis 
(Figure  3A). However, responses to the immunoprevalent 
epitopes tended to be lower during acute disease than in recov-
ered melioidosis patients, reaching significance in the case of 
BPSS1385 p18, BPSS1531 p12, BPSL2096 p6, and BPSL2522 p14 
(Figure 3B). Again, the markedly reduced response to strongly 
immunoprevalent epitopes during acute melioidosis argues 
a case for altered modulation of bacterial antigen expression 
or host antigen presentation. We further investigated whether 
acute melioidosis patients may generate responses to the selected 
immunoprevalent peptides after recovery from infection, looking 
at paired samples from individual donors, comparing acute and 
convalescent samples. We found that PBMC from septicemic 
patients lacked a response to the selected immunoprevalent 
peptides (at day 3), but could respond to them after completion 
of antibiotic treatment and recovery from infection (at day 30) 
(Figure  4). Responses to the immunoprevalent T-cell epitopes 
were 2–4 times greater at recovery.
DiscUssiOn
There are estimated to be around 90,000 deaths annually from 
melioidosis across the globe, making development of an effec-
tive vaccine a high priority (5). A detailed understanding of 
protective immunity to Bp necessarily underpins such efforts, not 
least since the most highly susceptible individuals may often be 
immune-compromised, as in the large SE Asian cohort in whom 
diabetes is a comorbidity (9, 30, 31). Furthermore, the considera-
tion of vaccine strategies for protection against melioidosis in a 
global health setting is highly overlapping with consideration of 
biodefense preparedness against use of either Bp or Bm as a bio-
weapon (9). While immunodominant antigens and correlates of 
protection are likely to show a high degree of overlap across these 
different settings, there are several key differences to consider in 
terms of detailed applications: while environmental Bp is likely 
to be encountered through contact with soil or water and to be 
of specific concern to susceptible individuals such as those with 
diabetes, weaponised Bp, or Bm is most likely to be used as an 
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aerosolized pathogen. If efforts to leverage vaccine approaches 
by identifying synergies between these different threats are to 
flourish, there will need to be greater attention paid to differences 
in immune mechanisms associated with these differential modes 
of exposure: what are the specific requirements of a vaccine that 
could serve both with respect to exposure of diabetic individuals 
through skin lesions, as well as of immune-competent individuals 
across the lung mucosa?
In recent years, there have been substantial efforts to identify 
key Bp antigens as vaccine candidates, most commonly through 
analyzing protective vaccination of mice from acute Bp infection 
(32–40). This screening strategy has offered a relatively large 
number of potential immunogens. However, our focus in the 
present study was to adopt an approach centered on the spec-
trum of disease outcomes in naturally exposed human cohorts. 
The murine models depend generally on a single, intraperitoneal 
injection of a lethal dose of Bp, with or without protective vac-
cination during the preceding weeks, then measuring survival 
during short-term, acute disease. The pattern of human exposure 
and disease is somewhat different to this. The leads offered by the 
short-term murine models of acute infection undoubtedly offer 
important indicators as to those immunogens capable of elicit-
ing an adaptive immune response that can significantly impact 
clearance of the input inoculum before there is a chance of sepsis. 
However, this perhaps sets the bar for protection at a different place 
to the challenge of conferring protection to immune-susceptible 
humans living in an environment supplying ongoing microbial 
exposure, and with a lack of any clear indication in human disease 
as to the immune correlates that distinguish asymptomatic and 
symptomatic outcomes.
In temperate countries, depending on soil and climatic condi-
tions, there may to a variable extent be a lifetime of exposure 
to Bp and closely related species such as Bt, from soil, drinking 
water, or rainwater spray, which can lead to seroconversion in a 
high proportion of individuals. Adaptive and/or innate defense 
mechanisms appear to render healthy individuals entirely imper-
vious to the consequences of continued, ongoing Bp exposure 
most of the time, except under conditions of enhanced immune 
susceptibility, often, diabetes. We were therefore fortunate to have 
the opportunity to conduct a large-scale T-cell epitope mapping 
screen of responses in exposed individuals from the Khon Kaen 
region of Thailand, comparing patterns of response between 
healthy seropositives, acute disease, and recovery. Mapping of 
T-cell activating peptides in a naturally exposed human cohort 
both provides crucial clues for the design of peptide-based vac-
cines, and also for monitoring specific immune responsiveness 
in the context of any trialed vaccines (28). While T-cell epitope 
mapping studies of large bacterial proteomes have often had to 
depend on screening very highly multiplexed cocktails of pooled 
peptides (41–45), we were keen here to obtain a pure picture of 
T-cell responder frequencies to individual sequences from the 
genome by screening against individual, overlapping peptides 
(28, 46). To this end, we conducted an in-depth analysis of 
human T-cell response to Bp peptide libraries. This showed the 
Bp proteome to be remarkably T-cell epitope rich. Two-hundred 
and thirty-five immunoprevalent peptides were identified from 
the top 20 candidate Bp antigens, i.e., capable of inducing a T-cell 
FigUre 2 | Differential IFNγ responses to 10 Burkholderia pseudomallei (Bp) immunoprevalent peptides in individuals that are seronegative for Bp, seropositive for 
Bp, or have recovered from acute melioidosis. Peripheral mononuclear cells (PBMCs) from seronegative (S−, n = 8), seropositive (S+ , n = 15), and individuals that 
have recovered from melioidosis (R, n = 15) were cultured with medium only control or paraformaldehyde (PFA) fixed Bp (a), or the top 10 immunoprevalent 
peptides (B). Horizontal lines represent mean value for each group. Statistical significance was determined using Mann–Whitney U test; ns, not significant, * 
p < 0.05 and ** p < 0.01.
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IFNγ response in ≥80% of tested seropositive human donors 
living in endemic area. Heatmap analysis of responses within 
the cohort enabled us to build a panel of 10 very commonly 
recognized immunoprevalent peptides, which cumulatively can 
account for around 1,000 SFC/106 cells––i.e., 0.1% of the periph-
eral T-cell repertoire. Patients who had recovered from septice-
mic melioidosis showed a high level of T-cell IFNγ response to 
these epitopes compared with patients with acute septicemic 
melioidosis. It was noteworthy that while the T-cell response 
to fixed Bp overall was intact during acute sepsis, specific T-cell 
responses to most of these key, immunoprevalent peptides had 
been shut down. The notion that as much as 0.1% of the periph-
eral T-cell repertoire is apparently devoted to recognition and 
control of this one bacterial pathogen is striking. We interpret 
the data to mean either that lifelong reexposure to a seemingly 
strongly immunogenic pathogen indeed leads to exceptionally 
high responder cell frequencies in individuals from endemic 
areas, and/or that these high frequencies may also be boosted by 
cross-reactive antigens from phylogenetically related bacterial 
species. For example, a number of the epitopes described here 
are largely conserved in Bt. We here undertook a detailed analy-
sis of conservation of all of the peptides analyzed, across all 20 
antigen libraries, looking at conservation between pseudomallei, 
thailandensis and mallei (Table S3 in Supplementary Material). 
It should be noted in this context that, though highly related, 
the size of the bacterial genomes across the two chromosomes 
runs pseudomallei > thailandensis > mallei, in increments of an 
8–9% contraction in each case. Thus, some of the key regions 
of Bp T-cell immunogenicity are absent from Bt and Bm. The 
situation can best be illustrated by considering the top 10 ranked 
FigUre 4 | Comparison of IFNγ responses to top six T-cell immunoprevalent 
peptides of Burkholderia pseudomallei (Bp) in patients with a diagnosis of 
acute melioidosis at the time of acute admission and following recovery 
having completed antibiotic treatment. Peripheral mononuclear cells (PBMCs) 
from patients diagnosed with acute melioidosis were cultured with medium 
only control, paraformaldehyde (PFA) fixed Bp, or T-cell immunoprevalent 
peptides for 48 h. IFNγ induction was quantified by ELISpot. The results 
show the comparison of individual IFNγ responses between samples taken 
on admission (acute, white bar) and discharge (day 30, black bar) from the 
same patients (n = 3). The differences were not statistically significant using 
Wilcoxon matched-pairs signed rank test.
FigUre 3 | IFNγ responses to Burkholderia pseudomallei (Bp) and T-cell 
immunoprevalent peptides in patients with acute septicemic melioidosis 
compared with recovered individuals. IFNγ response to the top six 
immunoprevalent peptides of Bp measured by ELISpot analysis of peripheral 
mononuclear cell (PBMC) taken from patients with a diagnosis of acute 
melioidosis (A, n = 9) and melioidosis recovered individuals (R, n = 10).  
(a) shows the results for medium only control and paraformaldehyde (PFA) 
fixed Bp. (B) shows the results for six immunoprevalent peptides. Statistical 
significance was determined using Mann–Whitney U test; ns, not significant, 
* p < 0.05 and ** p < 0.01.
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epitope-containing peptides (Table 4): of these 7/10 are present 
in all three bacteria and almost entirely conserved in sequence 
(BPSL2522 p13, BPSL2522 p14, BPSL2522 p21, BPSS0503 p18, 
BPSS1532 p44, BPSS1599 p12, BPSS1599 p18). Two are present 
in Bp but entirely absent from the Bt and Bm genomes (BPSS1385 
p14 and p18). One is present in Bp and Bt, but absent from Bm 
(BPSS0530 p43). The comparative analysis of immunogens between 
these genomes is highly informative, whether considering the 
potential for cross-reactive immunogenicity, such as in dual-
purpose vaccines for communal/biodefense use against Bp and 
Bm, or considering potential for species specific diagnostics to 
distinguish between Bp and Bt exposure.
The starting point for the present study was 20 serodominant 
antigens previously defined by ourselves with others on the basis 
of reactivity of patient antisera against a recombinant protein 
Bp antigen array (47). Here, we demonstrate that all 20 antigens 
which had been defined by their antibody reactivity also contain 
multiple T-cell epitopes. In most cases, these antigens have not 
been previously reported as targets of T-cell recognition. A note-
worthy feature contributing to the strength and breadth of the 
response to immunoprevalent peptides we describe here was 
that T-cell recognition was in most cases able to traverse highly 
diverse HLA class-II haplotypes (Table S1 in Supplementary 
Material), as reflected also in the relatively broad HLA-DR bind-
ing profiles (Table 3). While our binding analysis was in this case 
limited to HLA-DR heterodimers, we acknowledge that the same 
epitopes may often be presented by HLA-DP and DQ heterodi-
mers. For example, we have previously defined BPSL2096 p6 as 
an epitope that can be presented also through HLA-DQB1*0602 
TaBle 4 | Sequence homology between Burkholderia pseudomallei (Bp), Burkholderia thailandensis (Bt), and Burkholderia mallei (Bm) for the twenty most commonly recognized Bp epitopes.
antigen Peptide no. Peptide Burkholderia pseudomallei Burkholderia thailandensis% Burkholderia mallei%
homology sequence homology sequence
BPSS0530 P43 BPSS0530 [421-440] KQTLAGSAMALRIVGDFPDL 100 KQTLAGSAMALRIVGDFPDL 0 –
BPSL2522 P13 BPSL2522 [121-140] AAKIQGMNVEVVVATGYTDR 100 AAKIQGMNVEVVVATGYTDR 100 AAKIQGMNVEVVVATGYTDR
BPSL2522 P14 BPSL2522 [131-150] VVVATGYTDRIGSDKYNDRL 100 VVVATGYTDRIGSDKYNDRL 100 VVVATGYTDRIGSDKYNDRL
BPSS1385 P14 BPSS1385 [131-150] TDFGGLENYKELTGGADPFA 0 – 0 –
BPSL2522 P21 BPSL2522 [201-220] APDRRVEVEVVGTQEVQKTT 100 APDRRVEVEVVGTQEVQKTT 100 APDRRVEVEVVGTQEVQKTT
BPSS0530 P18 BPSS0530 [171-190] ALPIARVAGRNASRTVSLDP 100 ALPIARVAGRNASRTVSLDP 100 ALPIARVAGRNASRTVSLDP
BPSS1385 P18 BPSS1385 [171-190] DVPIDPTSIEYLENTSFAEH 0 – 0 –
BPSS1599 P21 BPSS1599 [201-220] TAACVVLGGAFAYWHHRAKV 75 TVACVaFGGAlAYWHHRAKl 100 TAACVVLGGAFAYWHHRAKV
BPSS1532 P44 BPSS1532 [431-450] AGAILGAVVTGVALVAAAFV 100 AGAILGAVVTGVALVAAAFV 100 AGAILGAVVTGVALVAAAFV
BPSS1599 P12 BPSS1599 [111-130] AVRDHAFMPNGDWVGSREEA 100 AVRDHAFMPNGDWVGSREEA 100 AVRDHAFMPNGDWVGSREEA
BPSS1599 P18 BPSS1599 [171-190] RRGGRPRTERWWALRPVERR 95 RRGGRPRTERWWALKPVERR 100 RRGGRPRTERWWALRPVERR
BPSS1599 P29 BPSS1599 [281-300] ECTPGTAHYAWARNGSNVRY 100 ECTPGTAHYAWARNGSNVRY 100 ECTPGTAHYAWARNGSNVRY
BPSS1599 P20 BPSS1599 [191-210] LSPRAALIAATAACVVLGGA 85 LSPRAALIAATVACVaFGGA 100 LSPRAALIAATAACVVLGGA
BPSS1599 P34 BPSS1599 [331-350] TPLADDSVVRTQLLARLQWL 90 TPLVDDSVVRTQLLsRLQWL 100 TPLADDSVVRTQLLARLQWL
BPSL0999 P19 BPSL0999 [181-200] QGMGASNPIADNATEAGRAQ 100 QGMGASNPIADNATEAGRAQ 100 QGMGASNPIADNATEAGRAQ
BPSL0999 P15 BPSL0999 [141-160] VGYTDSTGSAAHNQTLSQNR 100 VGYTDSTGSAAHNQTLSQNR 100 VGYTDSTGSAAHNQTLSQNR
BPSS1385 P21 BPSS1385 [201-220] VVIVNDGRLGHKFLIDLPAL 0 – 0 –
BPSS1385 P11 BPSS1385 [101-120] SNRVMWNDRYDTLLIARDPR 0 – 0 –
BPSS1385 P20 BPSS1385 [191-210] VNTLDSHKNYVVIVNDGRLG 0 – 0 –
BPSS1385 P10 BPSS1385 [91-110] SLMQSLSGESSNRVMWNDRY 0 – 0
Sequences of Bp peptides were compared with those for Bt (taxonomic identifier 57975) and Bm (taxonomic identifier 13373). Variations from the sequence for Bp are shown in red.
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and HLA-DQB1*0302 (19). While our study was designed with 
a view to delineation of HLAII/CD4 epitopes, we cannot exclude 
the possibility that the peptides we used may have also contained 
within them, shorter, CD8 epitopes. While the extent to which 
our 20-mer peptides could have accessed the HLAI biosynthetic 
pathway for reprocessing, loading, and presentation is presum-
ably limited, we have previously described examples of Bp pep-
tides capable of presentation to both CD4 and CD8 cells (19). As 
an intracellular pathogen that is likely to access the endogenous 
HLAI pathway, Bp presumably induces protective CD8 immunity 
as well as CD4, which will be an important focus for future studies 
(17, 19, 21).
Having established that Bp carries a very large number of highly 
immunogenic and epitope-rich CD4 antigens, and that most of 
these can bind to diverse HLA II alleles, the challenge now will be to 
use this knowledge to gain an improved understanding of bacterial 
pathogenesis. It is given that Bp comes under host control through 
both innate (48–50) and adaptive immunity (13, 16–18, 51), yet 
data on immune correlates of overt melioidosis are still limited 
(21). Previous work from our group on acute melioidosis donors 
focused on the observation that patients who survived acute infec-
tion showed a T-cell IFNγ response to AhpC significantly greater 
than those who died (19). According to the studies shown here, 
the CD4 IFNγ response to immunoprevalent Bp epitopes was sup-
pressed, but not the overall responses to whole bacteria. This is in 
line with accounts of immune suppression during bacterial sepsis, 
surviving patients showing a restoration of adaptive immunity 
with convalescence (52). Further analysis will be required to deter-
mine the extent to which specific immune shutdown during sepsis 
might be variously attributed to apoptosis, Treg control, and/or 
specific immune exhaustion. In addition, septicemic melioidosis 
patients display overexpression of many transcripts involved in 
inflammation and innate immune response processes (53–55) 
while transcripts associated with adaptive immune processes, 
including cytotoxicity, are underexpressed (53).
Any effective vaccine for melioidosis will need to provide 
broad population coverage and induce high-frequency, protec-
tive immunity against Bp. As with any vaccine strategy, Bp 
vaccination will be a trade-off between the immunogenicity 
of a live-attenuated vaccine (including Bt-based approaches) 
with the associated potential for adverse events, and the lesser 
immunogenicity but greater safety of subunit (including epitope-
based) approaches (56). Our findings suggest that multivalent 
Bp antigen constructs or multi-epitope string vaccines may offer 
readily generated, potent and safe means of achieving this goal. 
As with other subunit vaccine approaches, appropriate adjuvants 
for immunogenicity with minimal boosting will be paramount. 
The library of highly immunogenic, protection-correlated, CD4 
activating peptides described here encompass the ability to bind 
diverse HLA-DR alleles, suggesting that such epitope vaccines 
could be applicable across diverse populations.
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